Antibody-mediated vascular rejection of kidney allografts: A population-based study

The Lancet

Volumn 381, Issue 9863, 2013, Pages 313-319

  Lefaucheur, Carmen ^a   Loupy, Alexandre ^b,h   Vernerey, Dewi ^b   Duong Van Huyen, Jean Paul ^c   Suberbielle, Caroline ^d   Anglicheau, Dany ^e   Vérine, Jérome ^f   Beuscart, Thibaut ^b   Nochy, Dominique ^g   Bruneval, Patrick ^h   Charron, Dominique ^a   Delahousse, Michel ^a,b   Empana, Jean Philippe ^a,b   Hill, Gary S ^a,c   Glotz, Denis ^a,d   Legendre, Christophe ^a,g   Jouven, Xavier ^h  

^a Nephrology and Kidney Transplantation   (France)

^b Department of Immunology and Histocompatibility ^*  (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g FOCH HOSPITAL   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; OKT 3; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE VASCULAR REJECTION; ADULT; ANTIBODY MEDIATED VASCULAR REJECTION; ARTICLE; BLOOD GROUP ABO SYSTEM; CLINICAL ASSESSMENT; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T CELL MEDIATED VASCULAR REJECTION;

EID: 84872979797     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61265-3     Document Type: Article

References (36)

1. Evans RW, Manninen DL, Garrison LP Jr., et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312: 553-59.
2. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339-43.
3. Garcia GG, Harden P, Chapman J, for the World Kidney Day Steering Committee 2012. The global role of kidney transplantation. Lancet 2012; 379: e36-38.
4. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-62.
5. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-31.
6. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specifi c HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-406.
7. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classifi cation of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-60.
8. Sis B, Mengel M, Haas M, et al. Banff 09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-71.
9. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-23.
10. Sis B, Einecke G, Chang J, et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial infl ammation and scarring. Am J Transplant 2010; 10: 421-30.
11. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-41.
12. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832-41.
13. Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011; 11: 1478-87.
14. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant 2012; 12: 1004-16.
15. de Serre NP, Canioni D, Lacaille F, et al. Evaluation of c4d deposition and circulating antibody in small bowel transplantation. Am J Transplant 2008; 8: 1290-96.
16. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207: 1579-87.
17. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510-17.
18. Hill GS, Nochy D, Bruneval P, et al. Donor-specifi c antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975-83.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classifi cation of renal allograft pathology. Kidney Int 1999; 55: 713-23.
20. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria -an addition to the Banff 97 classifi cation of renal allograft rejection. Am J Transplant 2003; 3: 708-14.
21. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-107.
22. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-62.
23. Saldanha AJ. Java Treeview -extensible visualization of microarray data. Bioinformatics 2004; 20: 3246-48.
24. Loucaidou M, McLean AG, Cairns TD, et al. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting signifi cance of vascular rejection. Transplantation 2003; 76: 1120-23.
25. Shimizu T, Ishida H, Shirakawa H, et al. Clinicopathological analysis of acute vascular rejection cases after renal transplantation. Clin Transplant 2010; 24 (suppl 22): 22-26.
26. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-29.
27. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II: morphology, immunopathology, and pathologic classifi cation. J Am Soc Nephrol 2002; 13: 779-87.
28. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specifi c marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-99.
29. Loupy A, Hill GS, Suberbielle C, et al. Signifi cance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specifi c antibodies (DSA). Am J Transplant 2011; 11: 56-65.
30. Trpkov K, Campbell P, Pazderka F, Cockfi eld S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specifi c antibody: analysis using the Banff grading schema. Transplantation 1996; 61: 1586-92.
31. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides eff ective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-95.
32. Rocha PN, Butterly DW, Greenberg A, et al. Benefi cial eff ect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490-95.
33. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-80.
34. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specifi c antibodies: a pilot study. Transplantation 2010; 89: 1403-10.
35. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-41.
36. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides eff ective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754-61